SPX4,140.06-5.13 -0.12%
DIA328.42+0.45 0.14%
IXIC12,644.46-13.10 -0.10%

BRIEF-Better Therapeutics Completes Pivotal Trial Of BT-001 For Type 2 Diabetes

BRIEF-Better Therapeutics Completes Pivotal Trial Of BT-001 For Type 2 Diabetes

Reuters · 07/28/2022 07:34
BRIEF-Better Therapeutics Completes Pivotal Trial Of BT-001 For Type 2 Diabetes

- Better Therapeutics Inc BTTX:

  • BETTER THERAPEUTICS COMPLETES PIVOTAL TRIAL OF BT-001 FOR TYPE 2 DIABETES AND ANNOUNCES POSITIVE SECONDARY ENDPOINT RESULTS FOLLOWING THE EARLIER ANNOUNCEMENT OF POSITIVE PRIMARY ENDPOINT RESULTS

  • BETTER THERAPEUTICS INC - DATA DEMONSTRATES BT-001 WAS DURABLE WITH A1C REDUCTIONS CONTINUING TO IMPROVE AFTER 180 DAYS OF TREATMENT

  • BETTER THERAPEUTICS INC - ON TRACK TO SUBMIT A DE NOVO CLASSIFICATION REQUEST WITH FDA FOR BT-001 IN Q3 OF 2022

Source text for Eikon: ID:

Further company coverage: BTTX


((Reuters.Briefs@thomsonreuters.com;))